Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation

Histopathology

Volumn 45, Issue 2, 2004, Pages 180-186

  Pizem, J ^a   Cor A ^b   Gale, N ^a  

^a INSTITUTE OF PATHOLOGY   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Laryngeal squamous cell carcinoma; p53; Survivin

Indexed keywords

PROTEIN P53; SURVIVIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER SURVIVAL; CELL CYCLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNGEAL BIOPSY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4344604374     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01925.x     Document Type: Article

References (46)

1. Altieri DC. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003; 3; 46-54.
2. Tetsuhisa Y, Nobuhiko T. The role of survivin as a new target of diagnosis and treatment in human cancer. Med. Electron Microsc. 2001; 34; 20-32.
3. Altieri DC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab. Invest. 1999; 79; 1327-1333.
4. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 2001; 7; 542-547.
5. Mirza A, McGuirk M, Hockenberry TN et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 2; 2613-2622.
6. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 2002; 277; 3247-3257.
7. Gottlieb TM, Oren M. p53 and apoptosis. Sem. Cancer Biol. 1998; 8; 359-368.
8. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer 1994; 57; 1-9.
9. Rafferty MA, Fenton JE, Jones AS. The history, aetiology and epidemiology of laryngeal carcinoma. Clin. Otolaryngol. 2001; 26; 442-446.
10. Gandour-Edwards R, Gumerlock PH. Molecular pathology of head and neck cancer. In Barnes L ed. Surgical pathology of the head and neck. New York: Marcel Dekker, Inc., 2001; 114-121.
11. Nadal A, Campo E, Pinto J et al. P53 expression in normal, dysplastic and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors. J. Pathol. 1995; 175; 181-188.
12. Barnes L. Diseases of the larynx, hypopharynx, and esophagus. In Barnes L ed. Surgical pathology of the head and neck. New York: Marcel Dekker, Inc., 2001; 163-174.
13. Sasaki CT, Jassin B. Cancer of the pharynx and larynx. Am. J. Med. 2001; 111; 118-123.
14. Hirvikoski P, Kumpulainen E, Virtaniemi J et al. Enhanced apoptosis correlates with poor survival in patients with laryngeal cancer, but not with cell proliferation, bcl-2 or p53 expression. Eur. J. Cancer 1999; 35; 231-237.
15. Pulkkinen JO, Klemi P, Martikainen P, Grenman R. Apoptosis in situ, p53, bcl-2 and AgNOR counts as prognostic factors in laryngeal carcinoma. Anticancer Res. 1999; 19; 703-707.
16. Hotz MA, Bosq J, Zbaeren P et al. Spontaneus apoptosis and the expression of p53 and Bcl-2 family proteins in locally advanced head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 1999; 125; 417-422.
17. WAF1/CIP1, p53 and bcl-2 in laryngeal squamous cell carcinoma. Cancer 1998; 82; 2159-2165.
18. Pruneri G, Pignataro L, Carboni N et al. Cinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J. Clin. Oncol. 1999; 17; 3150-3159.
19. Kapranos N, Stathopoulos GP, Manolopoulos L et al. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res. 2001; 21; 521-528.
20. Kawasaki M, Toyoda M, Shinohara H et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001; 91; 2026-2032.
21. Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinoma. Ann. Surg. Oncol. 2001; 8; 305-310.
22. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumours. Cancer 2001; 92; 271-278.
23. Sarela AI, Verbeke CS, Ramsdale J, Davis CI, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br. J. Cancer 2002; 86; 886-892.
24. Nakanishi K, Tominaga S, Hiroi S et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2002; 441; 599-563.
25. Ito T, Shiraki K, Sugimoto K et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31; 1079-1085.
26. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behaviour and survival rate in endometrial carcinoma. Cancer Lett. 2002; 184; 105-116.
27. Reed JC. The survivin saga goes in vivo. J. Clin. Invest. 2001; 108; 965-969.
28. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-ΔEx3 and survivin-Δ2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999; 59; 6097-6102.
29. Mahotka C, Liebmann J, Wenzel M et al. Differential subcellular localisation of functionally divergent survivin splice variants. Cell. Death Differ. 2002; 9; 1334-1342.
30. Dong Y, Sui L, Watanable Y, Sugimoto K, Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res. 2002; 22; 2377-2382.
31. Blanc-Brude OP, Yu S, Simosa H, Conte MS, Sessa WC, Altieri DC. Inhibitor of apoptosis protein survivin regulates vascular injury. Nat. Med. 2002; 8; 987-994.
32. Tran J, Master Z, Yu JI, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 2002; 99; 4349-4354.
33. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Antiapoptosis gene, survivin, and prognosis in neuroblastoma. Lancet 1998; 351; 882-883.
34. Hall PA, Lane DP. p53 in tumor pathology: can we trust immunohistochemistry? - Revisited! J. Pathol. 1994; 172; 1-4.
35. Lu C-D, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998; 58; 1808-1812.
36. Igekuchi M, Hirooka Y, Kaibara N. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer 2002; 95; 1938-1945.
37. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diag. Mol. Pathol. 2002; 11; 33-40.
38. Ikeguchi M, Kaibara N. Survivin messenger RNA is a good prognostic biomarker for oesophageal carcinoma. Br. J. Cancer 2002; 87; 883-887.
39. Okada E, Murai Y, Matsui K et al. Survivin expression in tumour cell nuclei is predictive of favorable prognosis in gastric cancer patients. Cancer Lett. 2001; 163; 109-116.
40. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407; 770-776.
41. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21; 485-495.
42. Chakravarti A, Noll E, Black PM et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. Clin. Oncol. 2002; 20; 1063-1068.
43. Williams GT, Chritohlow MR, Hedge VL, O'Hare KB. Molecular failure of apoptosis: inappropriate cell survival and mutagenesis. Tox. Lett. 1998; 102; 485-489.
44. Zaffaroni N, Pennati M, Colella G et al. Expression of the antiapoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci. 2002; 59; 1406-1412.
45. Xia C, Xu Z, Yuan X et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol. Cancer Ther. 2002; 1; 687-694.
46. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Phr(34) by flavopiridol enhances tumour cell apoptosis. Cancer Res. 2003; 63; 230-235.